Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Share News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: DQ Entertainment, Tristel, ReNeuron

Tue, 03rd Apr 2012 12:39

DQ Entertainment, a producer of animation, visual effects, game art and live action entertainment content for the global media and entertainment industry, has won three new contracts for co-production. The first is with French broadcaster TF1 for the new 3D animated TV series of Robin Hood, the second is with Minika ATV for its new kids network in Turkey and the third is with Gaurmont Alphanim for the new 3D animated CGI TV series "Lanfeust". Tristel, a manufacturer of infection control, contamination control and hygiene products, has terminated its supply arrangement with Medichem International for disinfectants and cleaning products. Tristel will now directly market these products to veterinary practices, hospitals under Tristel related brands. Tristel is now free to address the veterinary market directly and to broaden its product offering within areas that it had not been directly involved with, including its core hospital marketplace. ReNeuron Group, a UK-based stem cell company, has announced a firm placing to raise up to £9.4m before expenses with the shares being sold at 4p each. The issue price represents a discount of around 21.2% to the mid-market closing price of 5.075p on the day before the placing was announced. In addition, investors in the placing are being issued warrants to subscribe for ordinary shares, which could raise up to another £8.1m for the company, before expenses, if the warrants are exercised. The company also said that to date no adverse reactions had been seen in the five stroke patients who have been administered with its ReN001 stem cell therapy treatment. The company expects to be able to apply for a phase II study next year. NR
More News
10 Sep 2020 16:01

UK TRADING UPDATE SUMMARY: Prime People Hurt As Covid Hits Job Market

UK TRADING UPDATE SUMMARY: Prime People Hurt As Covid Hits Job Market

Read more
3 Sep 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
12 Aug 2020 13:35

IN BRIEF: ReNeuron Adds Obotritia Rep To Board; Names New Chair

IN BRIEF: ReNeuron Adds Obotritia Rep To Board; Names New Chair

Read more
31 Jul 2020 16:22

ReNeuron gets patent allowance in the US

(Sharecast News) - Cell-based therapeutics developer ReNeuron Group announced on Friday that the US Patent and Trademark office (USPTO) has completed its examination of its application titled 'phenotype profile of human retinal progenitor cells', and has issued a notification of allowance for the issue of a patent.

Read more
31 Jul 2020 11:28

UK WINNERS & LOSERS SUMMARY: Pets At Home Up 15% On June Sales Bounce

UK WINNERS & LOSERS SUMMARY: Pets At Home Up 15% On June Sales Bounce

Read more
29 Jun 2020 20:39

IN BRIEF: ReNeuron Posts Encouraging Data On Eye Condition Treatment

IN BRIEF: ReNeuron Posts Encouraging Data On Eye Condition Treatment

Read more
25 Jun 2020 14:55

IN BRIEF: ReNeuron Signs Exosome Research Collaboration With US Firm

IN BRIEF: ReNeuron Signs Exosome Research Collaboration With US Firm

Read more
25 Jun 2020 11:22

ReNeuron Group inks research evaluation deal with US firm

(Sharecast News) - Cell-based therapeutics company ReNeuron Group announced on Thursday that it has signed a new research evaluation agreement with a major United States biotechnology company, in connection with the use of its proprietary exosomes for the delivery of novel gene silencing therapeutics.

Read more
17 Jun 2020 15:58

IN BRIEF: ReNeuron Gets Approval In US And UK For Expanded Drug Trial

IN BRIEF: ReNeuron Gets Approval In US And UK For Expanded Drug Trial

Read more
3 Apr 2020 11:41

UK TRADING UPDATE SUMMARY: Bagir Says Cash Insufficient To Carry On

UK TRADING UPDATE SUMMARY: Bagir Says Cash Insufficient To Carry On

Read more
24 Feb 2020 12:24

Positive hRPC Stem Cell Trial Data Prompts ReNeuron To Expand Study

Positive hRPC Stem Cell Trial Data Prompts ReNeuron To Expand Study

Read more
17 Feb 2020 10:29

Data From ReNeuron CTX Stem Cell Therapy Trial Published In Journal

Data From ReNeuron CTX Stem Cell Therapy Trial Published In Journal

Read more
18 Dec 2019 19:08

Woodford Transfers Series Of Holdings To New Manager Schroders

Woodford Transfers Series Of Holdings To New Manager Schroders

Read more
6 Dec 2019 10:42

ReNeuron cuts losses after Fosun licence payment

(Sharecast News) - ReNeuron Group on Friday reported a narrower interim loss after receiving payment from a Chinese licensee, while it also made progress in its clinical and research programmes.

Read more
6 Dec 2019 09:32

ReNeuron Reports "Strong Progress" Across Various Programmes

ReNeuron Reports "Strong Progress" Across Various Programmes

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.